← All stories
● Covered by 1 source · 1 reportMedium impact1 negative

Trump's Executive Order to Split MMR Vaccine Draws Criticism from Public Health and Pharma

🔄 Updated 1d ago
New to BrevFeed? We gather this story from every outlet covering it into one summary — ranked by real-world impact, not just the latest headline — so you never miss what matters. What is BrevFeed? →

Key points

  • Trump's order proposes splitting the MMR vaccine into three separate shots.
  • This would increase vaccine doses from two to six for children.
  • Individual measles, mumps, and rubella vaccines are not available in the US.
  • PhRMA, representing major drug companies, criticized the order.

Executive Order on Vaccine Policy

Donald Trump issued an executive order outlining a "gold standard" vaccine policy, which includes a directive to split the existing measles, mumps, and rubella (MMR) combination vaccine into three individual shots. The current MMR vaccine is administered in two doses, meaning the proposed change would increase the total number of shots for children to six.

Public Health Opposition

Public health and medical organizations, including the American Academy of Pediatrics, have strongly criticized the order. They describe it as "dangerous," "unscientific," and "misleading," expressing concerns about potential risks to children's health. These groups have consistently opposed anti-vaccine agendas.

Pharmaceutical Industry Pushback

The pharmaceutical industry, represented by PhRMA (which includes companies like GSK, Sanofi, Pfizer, Merck, and Johnson & Johnson), also voiced immediate opposition. PhRMA stated that the order "debases America’s vaccine policy." The industry highlights that individual measles, mumps, and rubella vaccines are not currently available in the US, and developing them would require significant investment without scientific justification, given the proven safety and effectiveness of the existing MMR vaccine.

Practical Implications

Implementing the executive order would necessitate pharmaceutical companies to invest heavily in the development, testing, and market introduction of new individual vaccines for measles, mumps, and rubella. This would be done despite decades of data supporting the safety, effectiveness, and convenience of the combined MMR vaccine.

✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →

The daily brief

One email each morning: the day's tech stories, clustered across outlets and summarized. No account needed.

One email a day. Unsubscribe in one click, any time.

Today's brief

Spend a few minutes, get the whole day. Every topic's top stories in one hands-free rundown — listen, watch, or read the transcript.

~7 min · 6 stories · Aug 15

▶ Play today's brief Listen on Spotify

New every morning, and the back catalogue is archived by date.

Reporting from

A recent executive order by Donald Trump proposes splitting the combined measles, mumps, and rubella (MMR) vaccine into three separate shots, which would increase the number of required vaccinations for children. This proposal has been met with strong opposition from public health organizations and the pharmaceutical industry, citing scientific and practical concerns.